Clinical Trial Update: Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating RAD001 (everolimus) for plexiform neurofibromas in Neurofibromatosis Type 1 was terminated, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type
• Plexiform Neurofibroma

Drugs mentioned

• RAD001 (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Plexiform Neurofibroma Associated With Neurofibromatosis Type 1 | Phase 2 | Status: TERMINATED | Results posted: 2016-05-12